

Luca Masucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6395289/publications.pdf>

Version: 2024-02-01

57
papers

3,381
citations

257450

24
h-index

149698

56
g-index

59
all docs

59
docs citations

59
times ranked

4344
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 369-378.	1.3	48
2	Validation of Two Commercial Multiplex Real-Time PCR Assays for Detection of SARS-CoV-2 in Stool Donors for Fecal Microbiota Transplantation. <i>Microorganisms</i> , 2022, 10, 284.	3.6	3
3	Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS407-TPS407.	1.6	3
4	Fecal Microbiota Transplantation: What's New?. <i>Microorganisms</i> , 2022, 10, 23.	3.6	4
5	How the gut parasitome affects human health. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210915.	3.2	19
6	Rummeliibacillus suwonensis: First Time Isolation from Human Feces by Culturomics. <i>Current Microbiology</i> , 2022, 79, .	2.2	0
7	Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient. <i>Bone Marrow Transplantation</i> , 2022, 57, 1600-1603.	2.4	3
8	Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. <i>Nature Communications</i> , 2021, 12, 1926.	12.8	22
9	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 264-266.	8.1	5
10	Donor program for fecal microbiota transplantation: A 3-year experience of a large-volume Italian stool bank. <i>Digestive and Liver Disease</i> , 2021, 53, 1428-1432.	0.9	10
11	Culturomic and quantitative real-time PCR analyses for early contamination of abutments with different surfaces: A randomized clinical trial. <i>Clinical Implant Dentistry and Related Research</i> , 2021, 23, 568-578.	3.7	4
12	Fecal microbiota transplantation for recurrent <i>C. difficile</i> infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. <i>Gut Microbes</i> , 2021, 13, 1994834.	9.8	21
13	Laboratory handling practice for faecal microbiota transplantation. <i>Journal of Applied Microbiology</i> , 2020, 128, 893-898.	3.1	7
14	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for <i>C. difficile</i> infection during the COVID-19 pandemic: A prospective cohort study. <i>Digestive and Liver Disease</i> , 2020, 52, 1390-1395.	0.9	16
15	Increased <i>Faecalibacterium</i> abundance is associated with clinical improvement in patients receiving rifaximin treatment. <i>Beneficial Microbes</i> , 2020, 11, 519-525.	2.4	13
16	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 4333.	12.8	82
17	Characterizing Peri-Implant and Sub-Gingival Microbiota through Culturomics. First Isolation of Some Species in the Oral Cavity. A Pilot Study. <i>Pathogens</i> , 2020, 9, 365.	2.8	14
18	Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. <i>PLoS ONE</i> , 2020, 15, e0231789.	2.5	58

#	ARTICLE	IF	CITATIONS
19	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 430-432.	8.1	108
20	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 1555-1563.	12.1	110
21	The Effect of Different Antibiotic Regimens on Bacterial Resistance: A Systematic Review. <i>Antibiotics</i> , 2020, 9, 22.	3.7	39
22	FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 1021.	2.4	48
23	A Literature Review of Metagenomics and Culturomics of the Peri-implant Microbiome: Current Evidence and Future Perspectives. <i>Materials</i> , 2019, 12, 3010.	2.9	58
24	Impact evaluation of a Critical Pathway for patients with <i>Clostridium difficile</i> infection: A pre-post analysis in a Third Level Referral Center. <i>International Journal of Infectious Diseases</i> , 2019, 80, 105-110.	3.3	3
25	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent <i>Clostridioides difficile</i> Infection Treated With Fecal Microbiota Transplantation or Antibiotics. <i>Annals of Internal Medicine</i> , 2019, 171, 695.	3.9	81
26	Fecal Microbiota Transplantation: A Potential Tool for Treatment of Human Female Reproductive Tract Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 2653.	4.8	71
27	Intestinal Parasitic Infections in Internationally Adopted Children. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 983-989.	2.0	10
28	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019, 68, 2111-2121.	12.1	290
29	<i>Clostridium difficile</i> : trend in an Italian Tertiary Care Hospital during fifteen years, 2002-2016. <i>Minerva Medica</i> , 2019, 110, 168-171.	0.9	3
30	Anti-tumor necrosis factor $\hat{\pm}$ therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis. <i>World Journal of Gastroenterology</i> , 2019, 25, 1465-1477.	3.3	11
31	Pyroelectric Effect Enables Simple and Rapid Evaluation of Biofilm Formation. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 15467-15476.	8.0	11
32	Actoxumab + bezlotoxumab combination: what promise for <i>Clostridium difficile</i> treatment?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 469-476.	3.1	5
33	Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. <i>Digestive Diseases</i> , 2018, 36, 56-65.	1.9	146
34	Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2313-2325.	2.4	29
35	Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory <i>Clostridium difficile</i> infection—single versus multiple infusions. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 152-159.	3.7	117
36	European consensus conference on faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2017, 66, 569-580.	12.1	793

#	ARTICLE	IF	CITATIONS
37	Predictors of failure after single faecal microbiota transplantation in patients with recurrent <i>Clostridium difficile</i> infection: results from a 3-year, single-centre cohort study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 337.e1-337.e3.	6.0	60
38	Culturomics: bacterial species isolated in 3 healthy donors for faecal microbiota transplantation in <i>Clostridium difficile</i> infection. <i>Microbiologia Medica</i> , 2017, 32, .	0.1	4
39	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. <i>Digestive Diseases</i> , 2016, 34, 269-278.	1.9	105
40	Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases. <i>Digestive Diseases</i> , 2016, 34, 279-285.	1.9	22
41	Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. <i>Transplantation Proceedings</i> , 2016, 48, 402-407.	0.6	26
42	Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. <i>Applied and Environmental Microbiology</i> , 2016, 82, 6633-6644.	3.1	85
43	<i>In vitro</i> effect of clarithromycin and alginate lyase against <i>helicobacter pylori</i> biofilm. <i>Biotechnology Progress</i> , 2016, 32, 1584-1591.	2.6	25
44	Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 835-843.	3.7	467
45	Risk factors and clinical outcomes of candidaemia in patients treated for <i>Clostridium difficile</i> infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 493.e1-493.e4.	6.0	29
46	Gut Microbiome Changes after Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1953-1953.	1.4	9
47	<i>Entamoeba dispar</i> : A Rare Case of Enteritis in a Patient Living in a Nonendemic Area. <i>Case Reports in Gastrointestinal Medicine</i> , 2014, 2014, 1-3.	0.3	6
48	Faecal transplantation for <i>Clostridium difficile</i> infection. Three cases treated in Italy. <i>Digestive and Liver Disease</i> , 2014, 46, 475.	0.9	6
49	Culture-guided treatment approach for <i>Helicobacter pylori</i> infection: Review of the literature. <i>World Journal of Gastroenterology</i> , 2014, 20, 5205.	3.3	38
50	Intestinal parasites isolated in a large teaching hospital, Italy, 1 May 2006 to 31 December 2008. <i>Eurosurveillance</i> , 2011, 16, .	7.0	49
51	A Patient with Acute Myeloid Leukemia and a Solid Mass in the Colon. <i>Clinical Infectious Diseases</i> , 2009, 49, 1897-1898.	5.8	1
52	Monoclonal antibody fragment from combinatorial phage display library neutralizes alpha-latrotoxin activity and abolishes black widow spider venom lethality, in mice. <i>Toxicon</i> , 2008, 51, 547-554.	1.6	21
53	First Italian case of cyclosporiasis in an immunocompetent woman: local acquired infection. <i>New Microbiologica</i> , 2008, 31, 281-4.	0.1	10
54	In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 110-114.	3.0	40

#	ARTICLE	IF	CITATIONS
55	Multicenter Comparative Evaluation of Six Commercial Systems and the National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida Species. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2953-2958.	3.9	58
56	Commercial systems for fluconazole susceptibility testing of yeasts: comparison with the broth microdilution method. <i>Diagnostic Microbiology and Infectious Disease</i> , 2000, 38, 29-36.	1.8	20
57	Polymerase chain reaction-reverse cross-blot hybridization assay in the diagnosis of sporotrichoid <i>Mycobacterium marinum</i> infection. <i>British Journal of Dermatology</i> , 1998, 139, 872-876.	1.5	35